On Nov. 13, 2020, the FDA approved the immunotherapy Keytruda in combination with chemotherapy to treat unresectable locally advanced or metastatic triple-negative, PD-L1-positive breast cancer.
Women with type 2 diabetes who take metformin to control their blood sugar appear to have a lower risk of estrogen-receptor-positive breast cancer.
The first screening mammography guidelines for breast cancer survivors age 75 and older encourage people and their doctors to come to a decision that is individualized for each person after discussing the benefits and risk of screening mammograms, as well as the person's preferences.
A study offers a first peek at the biology behind scalp cooling by finding that scalp cooling dramatically reduces the amount of chemotherapy medicine absorbed by the hair follicles.
Black women diagnosed with stage I to stage III estrogen-receptor-positive, axillary node-negative breast cancer were more likely to die from breast cancer than white women with similar diagnoses and similar Oncotype DX Breast Recurrence Scores.
Having surgery along with systemic treatments or with systemic treatments and radiation therapy can improve survival for women diagnosed with metastatic hormone-receptor-positive or HER2-positive breast cancer.
Nearly 75% of women surveyed who opted for mastectomy without reconstruction were satisfied with the results, but almost 25% said their decision to go flat was not supported by their surgeons.
By combining eight factors, a new tool called the Cancer and Aging Research Group-Breast Cancer score helps predict whether older people diagnosed with early-stage breast cancer will have serious side effects from chemotherapy.
A combination of exercise and mindfulness training seems better at easing fatigue in breast cancer survivors than either technique alone, according to a small study.
Postmenopausal women diagnosed with early-stage hormone-receptor-positive, HER2-negative breast cancer with one to three positive lymph nodes and an Oncotype DX Recurrence Score of 25 or lower being treated with hormonal therapy after surgery can safely skip chemotherapy.
Women diagnosed with stage I to stage III breast cancer who more closely followed a diet designed to reduce the risk of diabetes had better survival than women who didn't follow the diet as strictly.
Mindfulness meditation and survivorship education classes eased symptoms of depression in younger women treated for breast cancer.
It's common for doctors to fail to understand the severity of radiation therapy side effects in women treated with radiation after lumpectomy, especially younger women and Black women.
Up to 80% of women treated for breast cancer take at least one dietary supplement, but many women are not aware that the supplements they're taking may interact with hormonal therapy medicines.
On Dec. 16, 2020, the FDA approved the targeted therapy Margenza in combination with chemotherapy to treat people diagnosed with metastatic HER2-positive breast cancer who have been treated previously with two or more anti-HER2 regimens, at least one of which was for metastatic disease.
Women who have been treated for breast cancer are less likely than the average woman to get pregnant and have a higher risk of certain complications, such as preterm labor, but most deliver healthy babies and childbirth has no effect on their long-term survival.
Some women age 65 and older diagnosed with early-stage hormone-receptor-positive breast cancer with a low risk of the cancer coming back who have lumpectomy followed by hormonal therapy treatment may be able to skip radiation therapy after surgery.
There may be a link between taking beta blockers, a heart medicine, before being diagnosed with advanced-stage HER2-positive breast cancer and worse survival after being treated with anti-HER2 medicines.
Certain woman age 70 to 80 may be able to skip chemotherapy after surgery for early-stage HER2-positive disease and be treated with Herceptin alone.
Women diagnosed with early-stage HER2-positive breast cancer treated with Herceptin and Tykerb before surgery who had a pathologic complete response (pCR) had better survival than women who didn't have a pCR.
Adding Ibrance to Faslodex as a first treatment for advanced-stage or metastatic hormone-receptor-positive, HER2-negative breast cancer that either came back (recurred) more than 1 year after completing 5 or more years of hormonal therapy or was metastatic at first diagnosis improved progression-free survival compared to Faslodex alone.
Compared to standard chemotherapy, Trodelvy offered better outcomes for people diagnosed with previously treated metastatic triple-negative breast cancer.
Women who report worse quality of life factors, such as poor physical well-being, poor social well-being, and a history of depression, are more likely to stop hormonal therapy early.
Women treated with chemotherapy for breast cancer were no more likely to be infected with COVID-19 or die from COVID-19 than women treated with other medicines that don’t weaken the immune system.